Kane Biotech to Present Clinical Data and Showcase Products at SAWC Fall 2026

WINNIPEG, Manitoba, Oct. 07, 2026 /CourierPR/ -- Kane Biotech Inc., a biotechnology company focused on addressing microbial biofilms, will present clinical data and showcase its revyve product line at the Symposium on Advanced Wound Care (SAWC) Fall 2026, taking place from October 15 to 18 in Las Vegas, Nevada.

On Saturday, October 17, from 6:15 p.m. to 7:30 p.m. Pacific Daylight Time (PDT), Dr. Robert Huizinga will present three scientific posters at SAWC Fall 2026. The presentations will cover the modeled economic impact of moving chronic wounds toward healing trajectories, the compatibility of revyve with hypochlorous acid irrigation and standard wound-care practices, and the relationship between changes in tissue oxygenation and wound-area reduction. These posters are authored by a multidisciplinary team of clinical and scientific collaborators, including Kane Biotech.

Kane will also host Booth #544 in the SAWC Fall exhibit hall, where it will showcase its revyve product line and engage with clinicians, researchers, and other wound-care professionals. The company plans to meet with its existing distributors and prospective new distributors to discuss opportunities to expand product awareness and commercial reach in the United States and other markets.

The revyve portfolio currently includes U.S. FDA 510(k) cleared revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray, which are also approved by Health Canada. Kane is ISO 13485:2016 certified under the Medical Device Single Audit Program.

SAWC Fall is a four-day, multidisciplinary educational conference that brings together the wound-care community to advance healing, strengthen collaboration, and improve patient care. The 2026 program features practical education addressing chronic wounds, limb salvage, pressure-injury prevention, mobile wound care, reimbursement, compliance, and emerging technologies.

Kane Biotech's revyve portfolio currently includes U.S. FDA 510(k) cleared revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser. The wound gel and wound gel spray are also approved by Health Canada.